HC Wainwright Comments on Nkarta’s Q3 Earnings (NASDAQ:NKTX)

Nkarta, Inc. (NASDAQ:NKTX) – Equities researchers at HC Wainwright cut their Q3 2025 EPS estimates for shares of Nkarta in a research note issued to investors on Wednesday, August 13th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.31) per share for the quarter, down from their previous forecast of ($0.26). The consensus estimate for Nkarta’s current full-year earnings is ($1.70) per share. HC Wainwright also issued estimates for Nkarta’s Q4 2025 earnings at ($0.32) EPS, FY2025 earnings at ($1.38) EPS, FY2026 earnings at ($1.63) EPS, FY2027 earnings at ($2.00) EPS, FY2028 earnings at ($1.37) EPS and FY2029 earnings at ($0.88) EPS.

Several other equities analysts have also recently weighed in on the stock. Stifel Nicolaus lowered their price objective on shares of Nkarta from $14.00 to $12.00 and set a “buy” rating on the stock in a research note on Thursday. Wall Street Zen upgraded shares of Nkarta from a “sell” rating to a “hold” rating in a research note on Saturday. Needham & Company LLC reiterated a “buy” rating and issued a $10.00 price objective on shares of Nkarta in a research note on Wednesday. William Blair reiterated a “market perform” rating on shares of Nkarta in a research note on Thursday, May 15th. Finally, Mizuho decreased their target price on shares of Nkarta from $16.00 to $14.00 and set an “outperform” rating on the stock in a research note on Tuesday, June 10th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $13.60.

Nkarta Stock Up 5.9%

Shares of NASDAQ:NKTX opened at $2.33 on Friday. The firm’s 50 day moving average price is $1.93 and its 200-day moving average price is $1.89. Nkarta has a twelve month low of $1.31 and a twelve month high of $6.63. The stock has a market capitalization of $165.50 million, a PE ratio of -1.57 and a beta of 0.72.

Nkarta (NASDAQ:NKTX) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.06.

Institutional Investors Weigh In On Nkarta

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NKTX. Jefferies Financial Group Inc. raised its stake in Nkarta by 901.7% during the 4th quarter. Jefferies Financial Group Inc. now owns 2,504,219 shares of the company’s stock worth $6,236,000 after acquiring an additional 2,254,219 shares during the period. Tang Capital Management LLC raised its stake in Nkarta by 252.9% during the 4th quarter. Tang Capital Management LLC now owns 2,293,719 shares of the company’s stock worth $5,711,000 after acquiring an additional 1,643,719 shares during the period. JPMorgan Chase & Co. raised its stake in Nkarta by 138.7% during the 4th quarter. JPMorgan Chase & Co. now owns 2,537,922 shares of the company’s stock worth $6,319,000 after acquiring an additional 1,474,560 shares during the period. Jane Street Group LLC raised its position in shares of Nkarta by 118.7% during the first quarter. Jane Street Group LLC now owns 134,286 shares of the company’s stock valued at $247,000 after buying an additional 852,559 shares during the last quarter. Finally, Monaco Asset Management SAM bought a new stake in shares of Nkarta during the first quarter valued at approximately $1,496,000. Institutional investors own 80.54% of the company’s stock.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.